AR016671A1 - IMIDAZOIL RENT SUBSTITUTED WITH A FIVE HETEROCICLIC RING, SIX OR SEVEN MEMBERS CONTAINING A NITROGEN ATOM, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

IMIDAZOIL RENT SUBSTITUTED WITH A FIVE HETEROCICLIC RING, SIX OR SEVEN MEMBERS CONTAINING A NITROGEN ATOM, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR016671A1
AR016671A1 ARP980105620A ARP980105620A AR016671A1 AR 016671 A1 AR016671 A1 AR 016671A1 AR P980105620 A ARP980105620 A AR P980105620A AR P980105620 A ARP980105620 A AR P980105620A AR 016671 A1 AR016671 A1 AR 016671A1
Authority
AR
Argentina
Prior art keywords
alkyl
trihalomethyl
independently selected
substituted
ring
Prior art date
Application number
ARP980105620A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR016671A1 publication Critical patent/AR016671A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Imidazoilalquilo sustituido con un anillo heterocíclico de cinco, seis o siete miembros que contiene un átomo de nitrogeno, que comprende un compuesto quetiene la formula (I) o sales o solvatos farmacéuticamente aceptables del mismo, donde: X es ung rupo alquilo C1-7 de cadena recta o un grupo alqueno oalquileno C2-4; donde dichos grupos alquilo o alqueno están opcionalmente substituidos con hasta dos grupos R7; n es 0, 1 o 2; m es 0 a 4; p es 0 a 4; cuando mes 0 a 4, Y representa -SO2-,-CS-, - CO-, -CONR5-, -CO(CH2)wO-, (siendo w de 1 a 4), -COO-, -CON(OR5)-, -C(NR5)NR5-, -SO2NR5- o -CSNR5-; cuando m es 2 a 4, Yrepresenta todos los grupos precedentes en los cuales m es 0 a 4 y además, Y representa -COR5-, -O-, -NR5CONR5-, -NR5CO-,-NR5-, - OCONR5-, -NR5C(NR5)-,-NR5CSNR5-, -NR5CS-O-NR5SO2-, -NR5C(O)O-, o -CSNR2; cada R5 representa independientemente hidrogeno, alquilo o bencilo; R6 está seleccionado de: arilo;heteroarilo; un grupo heterocíclico de 3-7 miembros; arilosubstituido que tie ne 1-3 substituyentes independientemente seleccionados de alquilo, halogeno,trihalometilo, CN, NO2, OR10 o NR10R11, donde R10 y R11 están independientemente seleccionadas de H, alquilo o trihalometilo; heteroarilo substituido quetiene1-3 substituyen tes independientemente seleccionados de alquilo, halogeno, trihalometilo, CN, NO2, OR10 o NR10R11, donde R10 y R11 son tal como se han definidomás arriba; o heterocíclico substituido que tiene 1-3 substituyentesindependientemente seleccionados de al quil trihalometilo o NR10R11, donde R10 y R11 sontal como se han definido más arriba estando unidos dichos substituyentes a los átomos de C en el anillo de manera que la cantidad total de substituyentes enelanillo es de 1 a 3; y donde el anillo hete rocíclico contiene átomos de nitrogeno substituibles y estando dichos átomos de nitrogeno opcionalmente substituidoscon alquilo inferior; cuando Y es -SO2- entonces R6 además de los grupos precedentes,representan también alquilo C1-7 o un grupo -NR1 0R11 en el que R10 y R11son tal como se han definido previamente; cada R1 está independientemente seleccionado de hidrogeno, alquilo o trihalometilo; cada R7 está independientementeImidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing a nitrogen atom, comprising a compound having the formula (I) or pharmaceutically acceptable salts or solvates thereof, where: X is ung rupo C1-7 alkyl of straight chain or a C2-4 alkylene or alkylene group; wherein said alkyl or alkene groups are optionally substituted with up to two R7 groups; n is 0, 1 or 2; m is 0 to 4; p is 0 to 4; when month 0 to 4, Y represents -SO2 -, - CS-, - CO-, -CONR5-, -CO (CH2) wO-, (being w from 1 to 4), -COO-, -CON (OR5) -, -C (NR5) NR5-, -SO2NR5- or -CSNR5-; when m is 2 to 4, Y represents all the preceding groups in which m is 0 to 4 and in addition, Y represents -COR5-, -O-, -NR5CONR5-, -NR5CO -, - NR5-, - OCONR5-, - NR5C (NR5) -, - NR5CSNR5-, -NR5CS-O-NR5SO2-, -NR5C (O) O-, or -CSNR2; each R5 independently represents hydrogen, alkyl or benzyl; R6 is selected from: aryl; heteroaryl; a 3-7 heterocyclic group; arylsubstituted having 1-3 substituents independently selected from alkyl, halogen, trihalomethyl, CN, NO2, OR10 or NR10R11, where R10 and R11 are independently selected from H, alkyl or trihalomethyl; substituted heteroaryl having 1-3 substituents independently selected from alkyl, halogen, trihalomethyl, CN, NO2, OR10 or NR10R11, where R10 and R11 are as defined above; or substituted heterocyclic having 1-3 substituents independently selected from the quintal trihalomethyl or NR10R11, where R10 and R11 are as defined above with said substituents being attached to the C atoms in the ring so that the total amount of ring substituents is from 1 to 3; and where the rocyclic hete ring contains substitutable nitrogen atoms and said nitrogen atoms being optionally substituted with lower alkyl; when Y is -SO2- then R6 in addition to the preceding groups, they also represent C1-7 alkyl or a group -NR1 0R11 in which R10 and R11 are as previously defined; each R1 is independently selected from hydrogen, alkyl or trihalomethyl; each R7 is independently

ARP980105620A 1997-11-07 1998-11-06 IMIDAZOIL RENT SUBSTITUTED WITH A FIVE HETEROCICLIC RING, SIX OR SEVEN MEMBERS CONTAINING A NITROGEN ATOM, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AR016671A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96575497A 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
AR016671A1 true AR016671A1 (en) 2001-07-25

Family

ID=25510440

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105620A AR016671A1 (en) 1997-11-07 1998-11-06 IMIDAZOIL RENT SUBSTITUTED WITH A FIVE HETEROCICLIC RING, SIX OR SEVEN MEMBERS CONTAINING A NITROGEN ATOM, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (12)

Country Link
EP (1) EP1028956A1 (en)
JP (1) JP2001522845A (en)
KR (1) KR20010031839A (en)
CN (1) CN1285828A (en)
AR (1) AR016671A1 (en)
AU (1) AU1296799A (en)
CA (1) CA2309609A1 (en)
HU (1) HUP0102662A3 (en)
IL (1) IL135727A0 (en)
PE (1) PE130699A1 (en)
WO (1) WO1999024421A1 (en)
ZA (1) ZA9810186B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
FR2827863A1 (en) * 2001-07-27 2003-01-31 Sanofi Synthelabo New dihydropyrrolyl alkyl imidazole derivatives having histamine receptor antagonist activity for treatment of obesity, diabetes, and central nervous system disorders
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
CA2550012A1 (en) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
LT2937341T (en) 2004-12-30 2017-09-11 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2022175384A1 (en) * 2021-02-17 2022-08-25 Fundación Universidad Católica De Valencia San Vicente Mártir Small-molecule agents with antiviral activity against rna viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012107A1 (en) * 1991-12-18 1993-06-24 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
ZA929788B (en) * 1991-12-18 1993-06-22 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring.
WO1995006037A1 (en) * 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
WO1998006394A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists

Also Published As

Publication number Publication date
WO1999024421A8 (en) 1999-08-26
CA2309609A1 (en) 1999-05-20
IL135727A0 (en) 2001-05-20
AU1296799A (en) 1999-05-31
EP1028956A1 (en) 2000-08-23
JP2001522845A (en) 2001-11-20
ZA9810186B (en) 1999-05-06
WO1999024421A1 (en) 1999-05-20
HUP0102662A3 (en) 2003-01-28
CN1285828A (en) 2001-02-28
HUP0102662A2 (en) 2001-12-28
KR20010031839A (en) 2001-04-16
PE130699A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
PE20212302A1 (en) APOL1 INHIBITORS AND THEIR METHODS OF USE
IS2503B (en) New compounds
AR061422A2 (en) SELECTIVE CYCLE PEPTIDES, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND USE OF THEMSELVES IN THE PREPARATION OF MEDICINES
FR2658511B1 (en) NOVEL BENZIMIDAZOLE AND AZABENZIMIDAZOLE DERIVATIVES, THROMBOXANE RECEPTOR ANTAGONISTS; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR028531A1 (en) ORGANIC COMPOUNDS
CO5690588A2 (en) DERIVATIVES OF 4-TETRAZOLILO-4 PHENYLPIPERIDINE FOR PAIN TREATMENT
CO5031253A1 (en) RECEIVING ANTAGONISTS Y5 OF NEUROPEPTIDES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY27322A1 (en) NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER
AR029766A1 (en) QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION
HUP0300616A2 (en) Adamantane derivatives, process for their preparation, their use and pharmaceutical compositions containing them
CY1116183T1 (en) Piperazinoidions as antagonists of oxytocin receptors
UY27336A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
ECSP045483A (en) DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR USE
CO5280079A1 (en) NEW COMPOUNDS
ES2053451T3 (en) A PROCEDURE FOR THE PREPARATION OF A COMPOUND THAT HAS USEFUL PHARMACOLOGICAL PROPERTIES.
AR016671A1 (en) IMIDAZOIL RENT SUBSTITUTED WITH A FIVE HETEROCICLIC RING, SIX OR SEVEN MEMBERS CONTAINING A NITROGEN ATOM, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR031526A1 (en) NEW PHENYLPIPERAZINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHODS TO PREPARE COMPOUNDS AND COMPOSITIONS AND USE OF COMPOUNDS IN THE PREPARATION OF A MEDICINAL PRODUCT.
CY1106672T1 (en) 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE AS ANTISPLASICS
DE69003200D1 (en) Aryl-substituted amine derivatives can be used in cancer therapy.
AR006360A1 (en) DERIVATIVES OF 1,2,3,4-TETRAHIDRONAFTALENO SUBSTITUTED, USE OF THE SAME FOR THE PREPARATION OF MEDICINES AND PROCEDURE FOR THE PREPARATION.
RU97117350A (en) INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
AR016416A1 (en) FENIL-ALQUIL-IMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR039391A1 (en) CYCLOPENTENE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure